Isaralgagene Civaparvovec is a gene therapy commercialized by Sangamo Therapeutics, with a leading Phase II program in Fabry Disease. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Isaralgagene Civaparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Isaralgagene Civaparvovec is expected to reach an annual total of $138 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Isaralgagene Civaparvovec Overview

Isaralgagene civaparvovec (ST-920) is under development for the treatment of Fabry disease. The therapeutic candidate is a gene therapy that comprises recombinant adeno-associated virus vector serotype 2/6 (AAV2/6) encoding a human alpha-galactosidase A cDNA expressing galactosidase alpha (GLA) enzyme gene. It is formulated as solution and administered through intravenous route. It is developed based on the zinc finger protein (ZFP) Technology.

Sangamo Therapeutics Overview

Sangamo Therapeutics (Sangamo), formerly Sangamo BioSciences, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Fabry disease, Huntington’s disease, Alzheimer’s disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.

The company reported revenues of (US Dollars) US$110.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.3% over FY2020. The operating loss of the company was US$183.3 million in FY2021, compared to an operating loss of US$129.6 million in FY2020. The net loss of the company was US$178.3 million in FY2021, compared to a net loss of US$121 million in FY2020. The company reported revenues of US$26.5 million for the third quarter ended September 2022, a decrease of 9.9% over the previous quarter.

For a complete picture of Isaralgagene Civaparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.